FOXO4-DRI

What Is FOXO4-DRI?

FOXO4-DRI was designed by researchers studying cellular senescence, the state cells enter where they stop dividing but don't die, instead releasing inflammatory signals that can damage surrounding tissue. The peptide's design is based on FOXO4, a protein found at elevated levels in senescent cells, which normally works to keep p53, a protein that would otherwise trigger cell death, sequestered in the cell's nucleus.

FOXO4-DRI is built as a "D-retro-inverso" peptide, a mirror-image version of the natural sequence engineered to resist enzymatic breakdown, which disrupts the interaction between FOXO4 and p53 specifically inside senescent cells. Because FOXO4 is only mildly present in most normal cells, this disruption selectively triggers apoptosis in senescent cells while sparing healthy ones, a targeting property that distinguishes it from broader senolytic compounds.

What FOXO4-DRI is Being Researched For?

• Selective Clearance of Senescent Cells

  The foundational study found that FOXO4-DRI selectively induced cell death in senescent cells across multiple mouse models, restoring measures of fitness, fur density, and kidney function in aged mice, and neutralizing chemotherapy-induced toxicity when given alongside doxorubicin.^[1]

• Cartilage and Joint Tissue Research

  Research in human chondrocytes, the cells that produce and maintain cartilage, found that FOXO4-DRI removed more than half of senescent cells generated during cell expansion for cartilage repair procedures, without significantly affecting minimally expanded, less senescent cells.^[2]

• Reproductive Aging Research

  Separate research found FOXO4-DRI improved measures of sperm production in aged mice by reducing inflammatory secretions from senescent cells in the testes, extending the compound's research relevance beyond its original tissue models.

How FOXO4-DRI Works

• Disrupting a Cell-Survival Interaction Specific to Senescent Cells

  Research points to FOXO4-DRI blocking the interaction between FOXO4 and p53 inside the cell nucleus. In senescent cells, this interaction normally keeps p53 sequestered and prevents it from triggering apoptosis; disrupting it releases p53 to do its normal job.^[1]

• Selectivity Based on FOXO4 Expression Levels

  Research points to FOXO4-DRI's selectivity coming from the fact that FOXO4 itself is only mildly expressed in most healthy, non-senescent cells, which limits the peptide's disruptive effect largely to cells where FOXO4 is elevated, namely senescent ones.^[1]

• Structural Basis of the FOXO4-p53 Interaction

  More recent structural biology research has mapped exactly how the disordered regions of FOXO4-DRI and p53 interact at the molecular level, providing a more detailed foundation for understanding and potentially improving on the original peptide's design.

Reconstitution and Handling

FOXO4-DRI is typically supplied as a lyophilized powder in a sealed vial and reconstituted with bacteriostatic water before use in a research setting. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out before mixing. Keel Bio's calculator is a commonly used tool for this. Once reconstituted, the solution is kept refrigerated to help preserve its stability.

Key Takeaways

FOXO4-DRI stands out in aging research for its precisely defined mechanism: selectively disrupting a protein interaction that's specifically elevated in senescent cells, giving it a genuinely more targeted rationale than many broader senolytic approaches. Its research base spans general aging measures, cartilage biology, and reproductive aging in animal models, backed by increasingly detailed structural biology work. As with most compounds in this space, it remains entirely preclinical with no human trial data.

Frequently Asked Questions

Sources and Research

1. Baar MP, Brandt RMC, Putavet DA, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;169(1):132-147.
2. Huang Y, He Y, Makarcyzk MJ, Lin H. Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Front Bioeng Biotechnol. 2021;9:677576.